{"id":"NCT05091307","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","officialTitle":"A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-02","primaryCompletion":"2022-06-17","completion":"2022-11-15","firstPosted":"2021-10-25","resultsPosted":"2023-08-08","lastUpdate":"2025-05-25"},"enrollment":861,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["COVID-19 Prevention"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.COV2.S","otherNames":["VAC31518","JNJ-78436735"]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza Vaccine","otherNames":[]}],"arms":[{"label":"Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo","type":"EXPERIMENTAL"},{"label":"Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S","type":"PLACEBO_COMPARATOR"},{"label":"Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo","type":"EXPERIMENTAL"},{"label":"Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the non-inferiority (NI) of the humoral immune response of the 4 influenza vaccine strains after concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent standard-dose influenza vaccine versus the administration of a seasonal quadrivalent standard-dose influenza vaccine administered alone; and to demonstrate the NI of the binding antibody response after concomitant administration of Ad26.COV2.S vaccine and a seasonal quadrivalent standard-dose influenza vaccine versus the administration of Ad26.COV2.S vaccine administered alone.","primaryOutcome":{"measure":"Groups 1 and 2: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains 28 Days After the Administration of a Seasonal Quadrivalent Standard-dose Influenza Vaccine","timeFrame":"28 days after vaccination with seasonal quadrivalent standard-dose influenza vaccine (Day 29)","effectByArm":[{"arm":"Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo","deltaMin":306,"sd":null},{"arm":"Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S","deltaMin":393,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":31,"countries":["United States","Belgium","Poland"]},"refs":{"pmids":["39866854"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":382},"commonTop":["Covid-19","Nasopharyngitis"]}}